Go to industries

Healthcare

Critical guidance on your journey

With new and groundbreaking technology constantly challenging the status quo, the healthcare industry is progressing by leaps and bounds. But in an industry built on regulations, strategic partnerships are often the key to successfully developing businesses. Our passionate advisors, backed by sub-sector teams globally, use their deep expertise in M&A, growth equity and ECM, debt advisory and corporate finance services to find your competitive edge, navigate local customs and help you create the most suitable strategy.

Contact advisor
Worldwide
518
deals closed in Healthcare
Worldwide
Explore all our industry-related deals
Go to deals
Decopharma has been acquired by CTT
Healthcare | Logistics

Decopharma has been acquired by CTT

Decopharma has been acquired by CTT – Correios de Portugal, strengthening its position as a national reference in pharmaceutical logistics solutions. This strategic transaction marks an important step in the consolidation of the specialized logistics sector in Portugal, combining Decopharma’s expertise in healthcare logistics with CTT’s robust infrastructure and growth potential.

Learn more
Laboratório S. José has been acquired by SYNLAB
Business Support Services | Healthcare

Laboratório S. José has been acquired by SYNLAB

The private shareholders of Laboratório S. José have sold the company to SYNLAB.

Learn more
Olyos Group has acquired a controlling stake in NewScience
Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Learn more
“Oaklins’ efforts enabled us to join Banook and significantly enhance our impact on respiratory drug development. Together with an outstanding transaction team, we were able to efficiently integrate into the Banook platform, backed by Motion Equity Partners.”

Jan De Backer

CEO, Fluidda NV

Read more
Example: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=AT&includes=featured_images,tags&language=de-AT&limit=3&tags=healthcare 
Ours: https://newsroom-api.pr.co/v1/pressrooms/oaklins/tagged/press_releases?country=PT&includes=featured_images,tags&language=en&limit=1&tags=healthcare

New chapters, global ambitions: mid-market M&A in Q4

QUARTERLY M&A ACTIVITY: In Q4 2025, Oaklins' clients completed 93 transactions across sectors and regions, highlighting how business leaders are using M&A to drive growth, succession and strategic change.

Learn more

Talk to our local advisor

João Beirôco

Managing Partner
Lisbon, Portugal
Oaklins Portugal

Meet our global industry specialists

Antoine Lemaire

Partner
Paris, France
Oaklins France

Stuart Goodman

Partner
London, United Kingdom
Oaklins S&W

Michael Jewell

Partner
London, United Kingdom
Oaklins Cavendish